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Abstract. Glutamine RF-amide peptide (QRFP) belongs to 
the RFamide neuropeptide family, which is involved in a wide 
spectrum of biological activities, ranging from food intake and 
cardiovascular functioning to analgesia, aldosterone secre-
tion, locomotor activity and reproduction. Recently, QRFP 
has been demonstrated to exert its effects by activating the 
G protein-coupled receptor GPR103. QRFP is expressed in the 
brain and peripherally in the adipose tissue, bladder, colon, 
testis, parathyroid and thyroid gland, as well as in the prostate 
gland. Following lung cancer, prostate cancer constitutes the 
second most frequently diagnosed cancer among men, whilst 
obesity appears to be a contributing factor for aggressive pros-
tate cancer. In the present study, we sought to investigate the role 
of QRFP in prostate cancer, using two androgen-independent 
human prostate cancer cell lines (PC3 and DU145) as in vitro 
experimental models and clinical human prostate cancer 
samples. The expression of both QRFP and GPR103 at the gene 
and protein level was higher in human prostate cancer tissue 
samples compared to control and benign prostatic hyperplasia 
(BHP) samples. Furthermore, in both prostate cancer cell lines 
used in the present study, QRFP treatment induced the phos-
phorylation of ERK1/2, p38, JNK and Akt. In addition, QRFP 
increased cell migration and invasion in these in vitro models, 
with the increased expression of MMP2. Furthermore, we 
demonstrated that the pleiotropic adipokine, leptin, increased 
the expression of QRFP and GPR103 in PC3 prostate cancer 
cells via a PI3K- and MAPK-dependent mechanism, indicating 
a novel potential link between adiposity and prostate cancer. 
Our findings expand the existing evidence and provide novel 
insight into the implication of QRFP in prostate cancer.
Introduction
RFamide peptides comprise a family of neuropeptides 
which are characterized by a common carboxy-terminal 
motif consisting of an arginine (R) and an amidated 
phenylalanine (F) (1). Vertebrate RFamides are categorized 
into five groups, namely i) the neuropeptide FF (NPFF); 
ii) the prolactin-releasing peptide (PrRP); iii) the gonado-
tropin-inhibitory hormone (GnIH); iv) the kisspeptin (also 
known as metastin); and v) the 26RFa/QRFP group (2,3). 
The latter was initially identified in frog brain (4), with the 
N-extended longest form of the glutamine RF-amide peptide 
(QRFP) consisting of 43 amino acids, while due to several 
processing sites of this peptide a 26 (26RFa), 6 (26RFa20-26) 
and 9 (9RFa) amino acid form can also be produced (4-7). 
QRFP has been identified as the cognate ligand of the previ-
ously identified human orphan G protein‑coupled receptor 
(GPCR) GPR103 (8,9). Notably, GPR103 shares 48 and 47% 
protein sequence homology with the two orexin receptors, 
OX1R and OX2R, respectively (8).
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In the human brain, the QRFP gene has been found to 
be almost exclusively expressed in certain hypothalamic 
areas/nuclei, such as the lateral hypothalamic area (LHA), 
the ventromedial hypothalamic nucleus (VMH), the arcuate 
nucleus (Arc) and the paraventricular nucleus (PVN), which 
are involved in the regulation of the feeding behaviour (5,7). 
Outside the central nervous system (CNS), in humans, QRFP 
is also expressed in various endocrine glands (e.g., in the testis 
and the adrenal, thyroid and parathyroid glands), as well as in 
the prostate gland, where its expression is higher compared to 
that in the hypothalamus (7,8,10). According to its widespread 
expression, QRFP appears to be implicated in a number of 
biological functions/systems, including the regulation of 
feeding behaviour (11) and the control of the gonadotropic 
axis (12,13). Notably, the central administration of QRFP in 
mice has been demonstrated to result in increased arterial 
blood pressure (BP) and heart rate (HR), as well as in increased 
stress activity levels based on grooming behaviour (6).
In addition, 26RFa has been shown to be expressed in 
human prostate cancer and to stimulate the neuroendocrine 
differentiation and migration of androgen-independent DU145 
prostate cancer cells (14). Overall, prostate cancer is the 
fourth most common cancer globally, whilst it constitutes a 
leading cause of cancer-related mortality and the second most 
frequently diagnosed cancer among men, following only lung 
cancer (15,16). More than 1.1 million new prostate cancer cases 
were diagnosed worldwide in 2012 (17), whilst the global burden 
of prostate cancer is expected to keep increasing in the next 
decades in parallel to the increasingly ageing population (18). 
Notably, androgen deprivation/ablation therapy is the mainstay 
treatment option for advanced prostate cancer, which is initially 
effective in slowing the disease progression, since androgens 
stimulate prostate cancer growth (19). However, prostate cancer 
often progresses eventually to an androgen-independent state 
which is characterized by a poor prognosis (19).
Given the existing evidence indicating that 26RFa and 
GPR103 are present in prostate carcinomatous foci which 
exhibit neuroendocrine differentiation (14), in the present 
study, we aimed to further explore the role of both QRFP 
and GPR103 in prostate carcinogenesis by studying their 
expression in human prostate cancer samples and using two 
androgen-independent prostate cancer cells lines (PC3 and 
DU145) as in vitro experimental models.
Materials and methods
Prostate cancer cell lines cultures. The human androgen-inde-
pendent prostate cancer cell lines, DU145 and PC3, were 
purchased from the American Type Culture Collection 
(ATCC, Manassas, VA, USA) and were cultured in 75 cm2 cell 
culture flasks, in Ham's F12 (Sigma‑Aldrich, Gillingham, UK) 
and RPMI-1640 media (Invitrogen, Paisley, UK), respectively, 
supplemented with 10% fetal calf serum (FCS) (Thermo 
Fisher Scientific, Loughborough UK) and 5 ml of 100X anti-
biotic‑antimycotic (Thermo Fisher Scientific). All flasks were 
incubated in a humidified incubator at 37˚C in 5% CO2, and 
were routinely passaged at approximately 70‑80% confluency. 
Of note, although the PC3 cell line has been assigned twice 
under NCBI (catalogue number C427), this does not affect the 
outcomes of our study.
In vitro treatments. For the phosphorylation analyses, both the 
PC3 and DU145 cell lines were treated with QRFP (Phoenix 
Peptides, Burlingame, CA, USA; 100 nM) for up to 60 min 
at the following time-points: 0 (no supplement), 5, 15, 30 and 
60 min. For the cell invasion assays, cells were treated with 
QRFP for 8 h at 1, 10 and 100 nM. Epidermal growth factor 
(EGF; Sigma-Aldrich), at 50 ng/ml was also used as a positive 
control. For the same experiment, we used the PI3K inhibitor, 
LY294002 (Sigma-Aldrich), and the MAPK inhibitor, U0126 
(Sigma-Aldrich), both at 10 mM, in the presence or absence 
of QRFP. For the effects of adipokines, the PC3 cells were 
treated with leptin (100 nM), adiponectin (10 nM), and 
chemerin (1 nM) (R&D Systems, Abingdon, UK) for 24 h 
prior to assessing the levels of QRFP and GP103 by RT-qPCR. 
The same concentrations of LY294002 and U0126 were used.
Prostate tissue samples. Human prostate tissue samples 
(benign prostatic hyperplasia, n=5 and malignant, n=5) were 
obtained from men undergoing various prostate procedures, 
such as radical retro-pubic prostatectomy (RRP), transurethral 
prostate resection (TURP) or transrectal ultrasound (TRUS) 
and prostate biopsy, at the University Hospitals Coventry and 
warwickshire (UHCw) NHS Trust (date range of recruit-
ment/sample collection: November, 2010 to October, 2015). 
The present study was approved by the National Research 
Ethics Committee and the Research and Development depart-
ment of the UHCw NHS Trust (16/11/2010-1/10/2015) and was 
conducted according to the principles of good clinical practice 
and the recommendations of the Declaration of Helsinki. Men 
undergoing prostate surgery for either benign or malignant 
conditions or undergoing a prostate biopsy for suspected 
cancer either with an elevated age‑specific PSA or with an 
abnormal prostate investigation were approached for potential 
inclusion into the study. Patients were presented with a full 
explanation of the nature of the study, including the potential 
benefits and risks of taking part. All patients recruited into 
the study provided informed signed consent. All collected 
prostate tissue samples for the present study were immediately 
snap‑frozen in liquid nitrogen and stored at ‑80˚C until use. 
Radical prostatectomy specimens were removed en bloc 
and were formalin‑fixed, paraffin‑embedded as per standard 
hospital practice. The tissue samples were available for use in 
the present study after the hospital pathologist had issued a 
final pathology report on each specimen for grading/staging 
purposes.
Western blot analysis. Cell and tissue lysates were extracted 
using RIPA cell lysis buffer (Sigma-Aldrich) and a cell 
scraper or a homogeniser respectively, according to the 
manufacturers' guidelines. Protein concentrations were deter-
mined calorimetrically using the bicinchoninic acid (BCA) 
protein assay kit according to manufacturer's instructions 
(Sigma-Aldrich). Samples were subsequently prepared for 
gel electrophoresis prepared by the addition of 2X Laemmli 
buffer (Sigma-Aldrich), and boiled for 5 min. The proteins 
were separated by SDS-PAGE 8-10%, and transferred to 
polyvinylidene difluoride (PVDF) membranes at 100 V for 
1 h in a transfer buffer containing 20 mM Tris, 150 mM 
glycine and 20% methanol. PVDF membranes were blocked 
in Tris-buffered saline (TBS) containing 0.1% Tween-20 and 
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5% BSA for 1 or 2 h and were incubated with the relevant 
anti‑rabbit primary antibodies overnight at 4˚C. On the 
following day, these membranes were washed thoroughly 
four times in 60 min with TBS-0.1% Tween, before incubation 
with the appropriate secondary anti-rabbit antibody buffer 
(1:2,000 dilution; Sigma-Aldrich), for 1 h at room tempera-
ture. The antibodies (all anti-rabbit) used were: GPR103 
(1:3,000 dilution; Acris Antibodies, Herford, Germany), 
QRFP-43 (1:4,000 dilution; Phoenix Pharmaceuticals, 
Belmont, CA), ERK1/2, p38, JNK, AKT (all 1:1,000 dilution; 
both phospho and total; Cell Signaling Technology, Leiden, 
Netherlands), MMP2 (1:1,000 dilution) and GAPDH (1:5,000 
dilution; Sigma-Aldrich, Gillingham, UK) at concentrations 
recommended by the manufacturers. Antibody complexes 
were visualized using ECL‑Plus (Thermo Fisher Scientific), 
according to the manufacturer's instructions. The appro-
priate positive and negative controls were used. All densities 
were determined using a scanning densitometer coupled to 
scanning ImageQuant™ software 7.0 (GE Healthcare Life 
Sciences, Little Chalfont, UK).
RNA isolation, cDNA synthesis and reverse transcription‑ 
quantitative PCR (RT‑qPCR). Total RNA was extracted from 
the human prostate cancer tissue samples and cell lines using 
the Qiagen RNeasy plus Mini kit (Qiagen, Manchester, UK). 
RNA samples were then treated by RNase-free DNase to 
eliminate genomic DNA contamination. The extracted RNA 
purity and quantity was assessed by a NanoDrop spectropho-
tometer (Thermo Fisher Scientific). In addition, 1 µg of total 
RNA was reverse transcribed into cDNA, by using Moloney 
Murine Leukemia Virus (M-MuLV) Reverse Transcriptase 
and random hexamers primers (Thermo Fisher Scientific).
The relative expression of the genes of interest was 
assessed by quantitative polymerase chain reaction (qPCR) on 
an ABI7500 instrument (Applied Biosystems; Thermo Fisher 
Scientific, Inc., Waltham, MA, USA) using SYBR®-Green-PCR 
reaction mixture (Sigma Aldrich; Merck KGaA, Darmstadt, 
Germany). The primers used in the present study were as 
follows: for QRFP sense, 5'‑AGG CAG GAC GAA GGC AGT 
GA‑3' and antisense, 5'‑GAC CGA AGC GGA AGC TGA 
AG‑3'; for GPR103 sense, 5'‑CCA GTC TAC CGC TGT TGT 
GA‑3' and antisense 5'‑GCC AGA CCA CAC CTA GCA TT‑3' 
and; for GAPDH (as a reference gene) sense 5'‑TGC ACC 
ACC AAC TGC TTA‑3' and antisense, 5'‑GAT GCA GGG ATG 
ATG TTC‑3'. The thermocycling conditions were as follows: 
Hotstart 95˚C for 10 min (1 cycle); amplification at 95˚C for 
15 sec followed by at 60˚C for 60 sec (40 cycles) and dissocia-
tion curve at 60‑95˚C for 1 min (1 cycle). Negative controls 
for all the reactions included preparations lacking cDNA or 
RNA-lacking reverse transcriptase in place of the cDNA. 
RNAs were assayed from two to three independent biological 
replicates. RNA levels were expressed as a ‘relative quanti-
fication’ using the housekeeping gene GAPDH value. The 
2-ΔCt method was employed for comparing relative expression 
results between treatments in qPCR (20).
xCELLigence migration and invasion assays. Real-time 
cell proliferation, migration and invasion experiments were 
performed using the xCELLigence system (ACEA Biosciences, 
San Diego, CA, USA), consisting of the Real-Time Cell 
Analyzer Dual Purpose (RTCA-DP) instrument placed in a 
humidified incubator maintained at 5% CO2 and 37˚C, and cell 
invasion and migration (CIM) plates for cell migration and 
invasion according to the manufacturer's protocol. The RTCA 
software 1.2 (Roche, Basel, Switzerland) monitored cell prolif-
eration, reporting changes in the Cell Index (CI) following the 
treatment of the cells.
Statistical analysis. All results presented are expressed as the 
mean ± SD. A Student's t‑test was used to difference between 
2 groups. Comparisons between more than 2 groups were anal-
ysed by ANOVA (non-parametric) analysis followed by post 
hoc Tukey's multiple comparison test. Values were considered 
to be statistical significance set at either P<0.05, P<0.01 or 
P<0.001. All statistical analyses were performed using Graph 
Pad software 5.0 (La Jolla, CA, USA).
Results
Expression of QRFP and GPR103 in human prostate cancer 
clinical samples and cell lines. QRFP and GPR103 mRNA 
levels in human prostate tissue samples were determined by 
RT-qPCR, which revealed that the gene expression of both 
QRFP and GPR103 was significantly higher in the prostate 
cancer samples (n=5) compared to the samples from benign 
prostate hyperplasia patients (BPH; n=5) (Fig. 1A). Furthermore, 
this statistically significant difference was also detected at the 
protein level, with both QRFP and GPR103 being significantly 
upregulated in prostate cancer tissue samples compared to 
BPH (Fig. 1B). Using human prostate cancer tissue lysate 
from one of the patients described above as a positive control, 
we also revealed that both the androgen-insensitive prostate 
cancer cell lines (PC3 and DU145), which we used for in vitro 
experiments in the present study, expressed QRFP and GPR103 
at the protein level (Fig. 1C).
Effects of QRFP on the phosphorylation status of prostate 
cancer cell lines. To examine the signalling pathways which 
may be involved in the effects of QRFP on prostate cancer 
cells, the phosphorylation status of ERK1/2, p38, JNK and Akt 
was assessed in the two androgen-insensitive prostate cancer 
cell lines of the present study following QRFP treatment. The 
PC3 and DU145 cells were treated with QRFP (100 nM) for 
up to 60 min (0, 5, 15, 30 and 60 min time-points). This QRFP 
treatment resulted in the statistically significant activation of 
ERK1/2 in the treated PC3 and DU145 cells at 5 min (P<0.01 
and P<0.001, respectively) (Fig. 2A and B). In addition, the 
significantly increased p38 phosphorylation was observed at 
different time-points in these two cell lines. In PC3 cells, the 
significant activation of p38 was noted at 30 min (P<0.01), 
as well as at 15 and 60 min (P<0.05), compared to the basal 
levels. In DU145 cells, maximal activation of p38 was reached 
at 60 min (P<0.01) compared to basal levels (Fig. 2C and D). 
Furthermore, maximal JNK phosphorylation occurred at 
30‑60 min in PC3 cells (P<0.05; Fig. 2E), whilst in DU145 
cells, a biphasic response was noted at 5 and 60 min (P<0.01 
and P<0.05, respectively; Fig. 2F). Finally, Akt phosphoryla-
tion increased significantly in PC3 cells from 15 to 60 min of 
QRFP treatment (P<0.01; Fig. 2G), whilst a similar trend was 
also noted in the QRFP-treated DU145 cells, with maximal 
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Akt phosphorylation at 30 and 60 min (P<0.05 and P<0.01, 
respectively; Fig. 2H).
To demonstrate the specificity of these responses, we also 
employed a siRNA approach for the GPR103 receptor, using 
the PC3 cells and Akt phosphorylation as our experimental 
paradigm. Following siRNA transfection, the GPR103 mRNA 
levels significantly decreased in the transfected PC3 cells 
with increasing concentrations of siRNA, with the maximum 
reduction observed at the 10 nM siRNA concentration. 
Furthermore, QRFP‑induced Akt phosphorylation was signifi-
cantly decreased in the PC3 cells transfected with GPR103 
siRNA compared to the control PC3 cells (data not shown).
Effects of QRFP on cell migration and invasion in prostate 
cancer cell lines. Following the effects of QRFP treatment on 
the phosphorylation of key kinases in the two prostate cancer 
cell lines in our study, we hypothesised that this would further 
affect cell migration and invasion. To explore such effects, we 
used the xCELLigence system, and EGF 50 ng/ml as a positive 
control.
Our experiments revealed that there was a significant and 
concentration-dependent increase in cell migration (10 nM, 
P<0.05; and 100 nM, P<0.01, compared to basal) in 
QRFP-treated PC3 cells at 8 h of treatment (Fig. 3A). In 
DU145 cells statistical significance compared to basal 
levels was reached only at the highest QRFP concentra-
tion (100 nM; P<0.01; Fig. 3C). In both cell lines, only a PI3K 
inhibitor (LY294002; 10 mM) significantly inhibited the 
effect of the applied QRFP treatment. The use of a MAPK 
inhibitor (U0126; 10 mM) revealed a similar trend; however 
its effects did not reach to statistical significance in either 
PC3 (Fig. 3B) or DU145 (Fig. 3D) QRFP-treated cells.
Figure 1. (A) QRFP and its cognate receptor GPR103 mRNA expression in BHP and prostate cancer (malignant) samples (***P<0.001; n=5 per group, 
mean ± SD). (B) Representative western blots for QRFP and GPR103 and quantification of western blotting indicating significant protein expression levels 
of QRFP (14 kDa) and GPR103 (49 kDa) in human prostate cancer tissue (malignant) compared to BHP (**P<0.01, *P<0.5; n=5 per group; mean ± SD). 
(C) western blotting demonstrating that both the androgen-independent human prostate cancer cell lines (PC3 and DU145) used in the in vitro experiments 
of our study express QRFP and GPR103 at the protein level. Human prostate tissue lysate was used as a positive control. QRFP, glutamine RF-amide peptide; 
BHP, benign prostatic hyperplasia.
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Similarly, 8 h of QRFP treatment significantly increased 
the invasive ability of PC3 cells (10 nM; P<0.05 and 100 nM; 
P<0.01, compared to basal; Fig. 4A). In DU145 cells, a signifi-
cant effect on invasion was noted only at the highest used QRFP 
concentration (100 nM; P<0.05, compared to basal; Fig. 4B). 
Despite the effects of QRFP on cell migration and invasion, 
there was no apparent effect on overall cell proliferation in 
either cell line (data not shown).
Since there is strong evidence of the role of matrix 
metalloproteinases (MMPs) in the remodelling, including 
angiogenesis, of the extracellular matrix (ECM), in the present 
study, we also tested the hypothesis that MMP2 is involved 
in the effects of cellular invasion. The PC3 and DUP145 cells 
were incubated with 100 nM QRFP for up to 12 h and the 
expression of MMP2 was assessed at regular time-points 
(1, 2, 4, 6, 10 and 12 h) by western blotting. In PC3 cells, QRFP 
Figure 2. Representative western blots and quantitative analysis of signalling pathway-related molecules in androgen-independent (A, C, E and G) PC3 and 
(B, D, F and H) DU145 prostate cancer cells, demonstrating significantly increased phosphorylation status of (A and B) ERK1/2, (C and D) p38, (E and F) JNK, 
and (G and H) Akt. Cells were treated for 5, 15, 30 and 60 min with 100 nM QRFP (***P<0.001, **P<0.01, *P<0.05).
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treatment significantly induced MMP2 protein expression at 
1 to 6 h (all P‑values <0.05, compared to basal; Fig. 4C). In 
QRFP‑treated DUP145 cells, the highest significant increase 
was noted at 1 h (P<0.01), whilst significantly increased 
Figure 4. Effect of QRFP treatment on the cell invasion of (A) PC3 and (B) DUP145 cells using the xCELLigence system. Both cell lines were treated in a 
concentration-dependent manner (1, 10 and 100 nM) for 8 h. Treatment with the epidermal growth factor (EGF; 50 ng/ml) was used as positive control. Results 
were calculated by the xCELLigence Real-Time Cell Analyzer (RTCA) software (*P<0.05, **P<0.01, n=5; mean ± SD). (C and D) Representative western blots 
and quantification of the effect of treatment with 100 nM QRFP at varying time‑points (1, 2, 4, 6, 10 and 12 h) on the expression of MMP2 protein in (C) PC3 
and (D) DUP145 prostate cancer cells. Data presented as the mean ± SD from three independent experiments. *P<0.05, **P<0.01 compared to basal expression. 
GAPDH used as a loading control. 
Figure 3. The effect of QRFP treatment on the cell migration of (A) PC3 and (C) DU145 cell lines using the xCELLigence system. Both cell lines were 
treated in a concentration-dependent manner (1, 10 and 100 nM) for 8 h. Treatment with the epidermal growth factor (EGF; 50 ng/ml) was used as positive 
control. Results were calculated by the xCELLigence Real-Time Cell Analyzer (RTCA) software (*P<0.05 and **P<0.01 compared to basal, n=5; mean ± SD). 
(B and D) The effects of QRFP treatment (100 nM for 8 h) in the presence or absence of PI3K (PI3Ki:LY294002; 10 mM) and MAPK/ERK (UO126; 10 mM) 
inhibitors on migration signalling pathways in PC3 and DU145 cells. Data were evaluated using the xCELLigence RTCA software (#P<0.05 compared to basal; 
*P<0.05 and **P<0.01 compared to QRFP treatment; n=5; mean ± SD).
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levels were also documented at 4 to 10 h (all P‑values <0.05, 
compared to basal; Fig. 4D).
Effects of leptin on QRFP and GPR103 gene expression in PC3 
prostate cancer cells. Several studies have revealed an asso-
ciation between adipokines with prostate cancer progression. 
Thus, in this study, we also investigated whether QRFP and 
GPR103 gene expression in PC3 cells is regulated by certain 
key adipokines, namely leptin, adiponectin, and chemerin. 
Based on these experiments, only leptin significantly induced 
the expression of QRFP and GPR103 (Fig. 5A and C). This 
leptin‑induced effect was time‑dependent with a significant 
increase at 12 and 24 h (data not shown). Using specific 
inhibitors of PI3K (LY294002) and MAPK (U0126), we were 
also able to demonstrate that this leptin-induced effect was 
mediated via the PI3K and MAPK pathways (Fig. 5B and D).
Discussion
In the present study, we revealed that QRFP and its cognate 
receptor GPR103 were expressed in two androgen-independent 
human prostate cancer cell lines (PC3 and DU145), and that 
their expression was upregulated in human prostate cancer 
tissue samples compared to that in samples from benign 
prostate hyperplasia patients. These findings were in line with 
the data from Alonzeau et al (14), indicating that 26RFa was 
expressed in human prostate cancer, stimulating the neuro-
endocrine differentiation and migration of the DU145 cells. 
Based on these findings, we could not exclude the autocrine 
effects of this peptide, along with QRFP acting in an endocrine 
manner.
Our data also revealed that QRFP induced the phosphory-
lation of ERK1/2, p38, JNK and Akt in both prostate cancer 
cell lines used in the present study. It is already known that 
the MAPK regulates different cellular processes in prostate 
cancer, and that this signalling pathway is overexpressed 
in human prostate cancer compared to normal prostate 
tissue (21,22). Autocrine and paracrine-acting growth factors 
can induce the increased expression of the Ras/Raf/MEK/ERK 
pathway, which has been associated with progressive prostate 
cancer (21). Furthermore, Ras signalling has been implicated 
in cancer cell invasion and metastasis, whilst the activation 
of the EGFR-ERK1/2 pathway promotes the migration 
and invasion of prostate cancer cells (23). Conversely, there 
are data indicate the activated ERK-dependent apoptosis 
of prostate cancer cell lines (24). It should also be noted 
that, Ras/Raf/MEK/ERK levels are differentially expressed 
amongst cancers (25). Hence, while it is plausible that the 
activation of the Ras/Raf/MEK/ERK cascade could contribute 
to prostate cancer development, further research is required 
to elucidate these mechanisms in androgen-independent pros-
tate cancer lines which exhibit low expression levels of this 
cascade.
Unlike ERK1/2, p38 exhibits weak activation by 
mitogens, although it is strongly activated in response to 
various stressors, including inflammatory cytokines, UV 
radiation, and osmotic and heat shock (26). Notably, TNFα 
(a pro-inflammatory cytokine which is known to activate 
the MAPK stress response) has been shown to induce the 
apoptosis of the androgen-dependent LNCaP prostatic 
cancer cell line, but not that of androgen-independent PC3 
cells, while p38 appears to exert protective effects against 
this TNFα-induced apoptosis of LNCaP cells (27). Of note, 
the activation of p38 in prostate cancer may be a result of 
upregulated upstream kinases (MKK3/6) combined with 
downregulated MAPK phosphatases (28-30). Furthermore, 
p38 phosphorylation has been demonstrated in prostate cancer 
cell lines exposed to toxic agents, and this activation has been 
Figure 5. Effects on (A) QRFP and (C) GPR103 gene expression in the PC3 prostate cancer cell line following 24 h of treatment with leptin (100 nM) or 
adiponectin (10 nM) or chemerin (1 nM). Data presented as the mean ± SD. Only the applied leptin treatment significantly increased QRFP and GPR103 
mRNA levels at 24 h (**P<0.01, compared to basal; experiment performed in triplicate). (B and D) Effects of PI3K (PI3Ki: LY294002) and MAPK (UO126) 
inhibitors in the presence or absence of leptin on (B) QRFP and (D) GPR103 gene expression (data presented as the mean ± SD; *P<0.05, **P<0.01 compared 
with basal levels; #P<0.05 and ##P<0.01 compared to leptin treatment; the experiment was performed in triplicate).
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implicated in apoptosis (31,32). Furthermore, it has been 
demonstrated that prostate cancer cell invasion was mediated 
via the p38 MAPK pathway, leading to phosphorylation of the 
heat shock protein 27 (HSP27) that in turn regulated MMP2 
activation and cell invasion (33). In addition, Chen et al (34) 
revealed that the stimulation of the G protein-coupled P2Y 
purinoceptor (metabotropic GPCR family) can induce prostate 
cancer cell invasion, which was regulated via the activation of 
the p38 pathway (34). It becomes evident that the activation of 
p38 plays a significant role in prostate cancer, and additional 
research is clearly needed to further explore the exact impli-
cations of the QRFP-induced p38 phosphorylation that was 
observed in the two androgen-independent prostatic cancer 
cell lines in the present study.
Furthermore, in the present study, we revealed the 
QRFP-mediated the activation of the JNK pathway in 
androgen-independent prostate cancer cells (PC3 and DU145). 
It is known that JNK is activated by certain growth factors and 
stressors (e.g., UV radiation) (35). In turn, this JNK activation 
frequently results in cell death via the activation of the mito-
chondrial apoptotic pathway in various cell types, including 
prostate cancer PC3 and DU145 cells, where JNK-initiated 
Fas-mediated apoptotic signals are considered to play a 
significant role in chemosensitivity (35,36). It has also been 
revealed that, depending on the cell type and stimulus, JNK 
can activate several transcription factors (e.g., c-Jun, c-Fos, 
Elk-1, c-My, ATF-2 and p53), as well as various members of 
the Bcl-2 family (37,38). JNK appears to regulate apoptosis via 
two distinct mechanisms: i) By promoting the phosphorylation 
of c-Jun and ATF-2 which results in the activation of AP-1 
and the expression of Fas/FasL signalling pathway-related 
proteins, which further mediates the activation of certain 
caspases (caspase-8 and -3) that trigger apoptosis; and ii) by 
mediating the phosphorylation of the anti-apoptotic proteins, 
Bcl-2/Bcl-xL, thus altering mitochondrial membrane potential 
and resulting in the release of cytochrome c and the activation 
of caspase-9 and -3 to induce apoptosis (39).
In the present study, we also observed a marked promoting 
effect of QRFP on the activation of Akt signalling in both 
human prostate cell lines used, with a higher degree of 
phosphorylation in PC3 compared to DU145 cells. The latter 
finding may be attributed to the higher expression of Akt in 
PC3 cells (40). Using siRNA for the cognate GPR103 receptor, 
we further demonstrated that the QRFP-induced response 
was receptor‑specific. Notably, the Akt signalling pathway 
can be activated by several cytokines, growth factors and 
oncogenes (41), whilst the phosphorylation of PI3K/Akt may 
contribute to the induction of tumour invasiveness and cancer 
development. The PI3K/Akt pathway activation has been more 
frequently associated with prostate cancer progression toward 
resistant/metastatic disease (42). Therefore, it has been consid-
ered that the PI3K/Akt pathway plays a role in the progression 
of prostate cancer, with the inhibition of the Akt pathway 
significantly affecting the EGFR‑induced prostate cancer cell 
migration (43).
Collectively, the PI3K/Akt/mTOR signalling pathway has 
been revealed to regulate multiple cellular processes, such 
as cell survival, metabolism, proliferation, migration and 
angiogenesis. Accordingly, the ERK and PI3K/Akt pathways 
are critical for the regulation of cancer cell survival and 
proliferation. Indeed, in prostate cancer, activated ERK and 
Akt translocate to the nucleus, inducing various downstream 
effects (e.g., cell proliferation, migration, invasion and angio-
genesis) (44). Furthermore, the activation of ERK1/2 promotes 
cell migration and invasion in prostate cancer cells (37,45). Of 
note, in this study, QRFP significantly induced the migration 
and invasion of both PC3 and DU145 cells. The inhibition 
of the PI3K/Akt pathway significantly reduced the effects of 
QRFP (100 nM) on the migration of both PC3 and DU145 cells. 
On the other hand, the inhibition of MAPK/ERK with U0126 
inhibited only partially the effect of QRFP, without reaching 
statistical significance. Although there was no effect of QRFP 
on cell proliferation, in a recent study by Ljujic et al (46), it 
was evident that the addition of both inhibitors to PC3 cells 
on their own significantly reduced cell viability. Similarly, in 
another study by Rybak et al (47), using DU145 cells, treat-
ment with U0126 resulted in the reduction of cell propagation. 
Therefore, we could not exclude the direct effects of these two 
inhibitors. Future studies using a wider repertoire of inhibitors 
should provide a better insight into the involvement of MAPK 
and PI3K in these responses.
Notably the expression of MMPs is associated with the 
migration, invasiveness and metastatic potential of prostate 
cancer cell lines (48). Recent data have also indicated a 
connection between the ERK1/2 signalling activation and 
MMPs (49). Indeed, the upregulated expression of MMPs 
has been linked to MAPK (ERK, p38, JNK) and Akt path-
ways (50). Furthermore, it has been also shown that the p38 
MAPK pathway is required for the TGF-β-mediated MMP2 
induction and increased cell invasion in prostate cancer (51). 
In the present study, we focused primarily on MMP2, since 
an increase in its expression has been reported in prostate 
cancer and appears to correlate with a larger tumour size (52). 
A recent study indicated that the expression of MMP2 was 
observed in metastatic cancer, but not in micro-metastasis, 
strongly proposing that increased MMP2 expression was 
related with prostate cancer development and metastasis (53). 
However, we acknowledge that activated MMP2 can activate 
other MMPs, such as MMP-9 through enzymatic cleavage. 
Therefore, future studies are warranted to also concentrate 
on other MMPs, as well as the use of gelatin zymography to 
determine their effect.
It is plausible therefore, that the activation of MMP2 
and the subsequent induction of cell invasion involved the 
MAPK/PI3K/Akt signalling pathways in accordance with the 
findings of the cell migration and invasion experiments in the 
present study. In the study by Ljujic et al, alpha-1-antitrypsin 
antagonized cisplatin-induced cytotoxicity in PC3 cells, an 
effect that was differentially mediated by ERK or Akt inhibi-
tors (46). Furthermore, as displayed in Fig. 5, the effect of 
the inhibitors on QRFP and GPR103 expression was similar 
in terms of leptin inhibition, but in terms of cell migration, 
treatment with U0126 failed to reach statistical significance. 
It is possible therefore, that overlapping and distinct pathways 
are operating in these cells to perform specific functions. For 
example, there is an abundance of evidence that mTOR signal-
ling is implicated in prostate cancer. Upstream of mTORC1, 
TSC1/TSC2 complexes can be phosphorylated by either Akt 
or ERK1/2. Thus, there is a possibility of convergence of those 
two signalling pathways at this point.
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Finally, there are data indicating that obesity may be 
associated with a higher risk of advanced/aggressive prostate 
cancer, potentially through the effects of adipose-tissue derived 
factors/hormones, collectively termed adipokines (e.g,. leptin 
which constitutes the prototype adipokine) (54-57). Although 
available data on leptin and the expression of leptin receptor 
in human prostate and relevant prostate cell lines are contra-
dictory, the existing evidence indicates that this pleiotropic, 
pro-inflammatory adipokine may exert varying effects on 
prostate cancer at different stages of its progression (56,58). Of 
note, it has been revealed that in the androgen-resistant PC3 
and DU145 prostate cancer cell lines, leptin can increase cell 
growth in a dose-dependent manner and induce ERK1/2 phos-
phorylation and JNK activation, whereas these leptin-induced 
effects are less prominent or absent in the androgen-sensitive 
LNCaP prostate cancer cells (59,60). In the experiments of 
the present study, only leptin, but neither adiponectin nor 
chemerin, was demonstrated to significantly induce the gene 
expression of both QRFP and its cognate GP103 receptor in the 
PC3 androgen-independent prostate cancer cell line. Notably, 
recent data indicated that the leptin-induced stimulatory 
effects on the proliferative activity of prostate cancer cell lines 
depend on the expression of the variant 1 isoform of the leptin 
receptor (LEPR var 1; OB-R) (58). Previous data have also 
indicated that JNK mediated the leptin-stimulated cell prolif-
eration of androgen-independent prostate cancer cells through 
STAT3 and Akt (61). In our experiments, we demonstrated 
that the inhibition of both the MAPK/ERK and PI3K/Akt 
pathways significantly abated the leptin‑induced effect on the 
expression of QRFP and GPR103 in the androgen-independent 
PC3 prostate cancer cell line.
Collectively, the present study provided novel insight into 
the effects of QRFP in human prostate cancer. Our present 
findings also indicated that the adipokine, leptin, modulated 
the expression of QRFP and GPR103 in an androgen-inde-
pendent human prostate cancer cell line via a PI3K- and a 
MAPK-dependent mechanism, thus providing a potential link 




This study was funded by the UHCw NHS Trust and the 
Libyan Embassy in the UK.
Availability of data and materials
The datasets used and/or analyzed during the current study are 
available from the corresponding author on reasonable request.
Authors' contributions
HSR and EK were involved in the conception and design of 
the study. MABK was involved in the development of the 
methodology. MABK, MR, Kw and JJ were involved in the 
acquisition of the data. MABK, HSR, EK and IK were involved 
in the analysis and interpretation of the data. HSR, EK and IK 
were involved in the writing, reviewing and/or revision of the 
manuscript. HSR supervised the study. All authors read and 
approved the final manuscript.
Ethics approval and consent to participate
The present study was approved by the National Research 
Ethics Committee and the hospital Research and Development 
department and was conducted according to the principles 
of good clinical practice and the recommendations of the 
Declaration of Helsinki. All patients who were recruited in the 
study provided informed written consent.
Patient consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
References
 1. Findeisen M, Rathmann D and Beck-Sickinger AG: RFamide 
peptides: Structure, function, mechanisms and pharmaceutical 
potential. Pharmaceuticals 4: 1248-1280, 2011.
 2. Ukena K, Vaudry H, Leprince J and Tsutsui K: Molecular evolu-
tion and functional characterization of the orexigenic peptide 
26RFa and its receptor in vertebrates. Cell Tissue Res 343: 
475-81, 2011.
 3. Sandvik GK, Hodne K, Haug TM, Okubo K and weltzien FA: 
RFamide peptides in early vertebrate development. Front 
Endocrinol 5: 203, 2014.
 4. Chartrel N, Dujardin C, Anouar Y, Leprince J, Decker A, 
Clerens S, Do-Régo JC, Vandesande F, Llorens-Cortes C 
Costentin J, et al: Identification of 26RFa, a hypothalamic neuro-
peptide of the RFamide peptide family with orexigenic activity. 
Proc Natl Acad Sci USA 100: 15247-52, 2003.
 5. Bruzzone F, Lectez B, Tollemer H, Leprince J, Dujardin C, 
Rachidi w, Chatenet D, Baroncini M, Beauvillain JC, Vallarino M, 
et al: Anatomical distribution and biochemical characterization 
of the novel RFamide peptide 26RFa in the human hypothalamus 
and spinal cord. J Neurochem 99: 616-627, 2006.
 6. Takayasu S, Sakurai T, Iwasaki S, Teranishi H, Yamanaka A, 
williams SC, Iguchi H, Kawasawa YI, Ikeda Y, Sakakibara I, 
et al: A neuropeptide ligand of the G protein-coupled receptor 
GPR103 regulates feeding, behavioral arousal, and blood pres-
sure in mice. Proc Natl Acad Sci USA 103: 7438-7443, 2006.
 7. Leprince J, Bagnol D, Bureau R, Fukusumi S, Granata R, 
Hinuma S, Larhammar D, Primeaux S, Sopkova-de Oliveiras 
Santos J, Tsutsui K, et al: The Arg-Phe-amide peptide 
26RFa/glutamine RF-amide peptide and its receptor: IUPHAR 
Review 24. Br J Pharmacol 174: 3573-3607, 2017.
 8. Jiang Y, Luo L, Gustafson EL, Yadav D, Laverty M, Murgolo N, 
Vassileva G, Zeng M, Laz TM, Behan J, et al: Identification 
and characterization of a novel RF-amide peptide ligand for 
orphan G-protein-coupled receptor SP9155. J Biol Chem 278: 
27652-27657, 2003.
 9. Fukusumi S, Yoshida H, Fujii R, Maruyama M, Komatsu H, 
Habata Y, Shintani Y, Hinuma S and Fujino M: A new peptidic 
ligand and its receptor regulating adrenal function in rats. J Biol 
Chem 278: 46387-46395, 2003.
10. Baribault H, Danao J, Gupte J, Yang L, Sun B, Richards w and 
Tian H: The G-protein-coupled receptor GPR103 regulates bone 
formation. Mol Cell Biol 26: 709-717, 2006.
11. Moriya R, Sano H, Umeda T, Ito M, Takahashi Y, Matsuda M, 
Ishihara A, Kanatani A and Iwaasa H: RFamide peptide QRFP43 
causes obesity with hyperphagia and reduced thermogenesis in 
mice. Endocrinology 147: 2916-2922, 2006.
12. Navarro VM, Fernández-Fernández R, Nogueiras R, Vigo E, 
Tovar S, Chartrel N, Le Marec O, Leprince J, Aguilar E, 
Pinilla L, et al: Novel role of 26RFa, a hypothalamic RFamide 
orexigenic peptide, as putative regulator of the gonadotropic axis. 
J Physiol 573: 237-249, 2006.
KAwAN et al:  THE ROLE OF QRFP IN PROSTATE CANCER 1149
13. Patel SR, Murphy KG, Thompson EL, Patterson M, Curtis AE, 
Ghatei MA and Bloom SR: Pyroglutamylated RFamide 
peptide 43 stimulates the hypothalamic-pituitary-gonadal axis 
via gonadotropin-releasing hormone in rats. Endocrinology 149: 
4747-4754, 2008.
14. Alonzeau J, Alexandre D, Jeandel L, Courel M, Hautot C, 
El Yamani FZ, Gobet F, Leprince J, Magoul R, Amarti A, et al: 
The neuropeptide 26RFa is expressed in human prostate cancer 
and stimulates the neuroendocrine differentiation and the 
migration of androgeno-independent prostate cancer cells. Eur 
J Cancer 49: 511-519, 2013.
15. Ørsted DD, Bojesen SE, Nielsen SF and Nordestgaard BG: 
Association of clinical benign prostate hyperplasia with prostate 
cancer incidence and mortality revisited: A nationwide cohort 
study of 3,009,258 men. Eur Urol 60: 691-698, 2011.
16. Ervik M, Lam F, Ferlay J, Mery L, Soerjomataram I and Bray F: 
Cancer Today. Lyon, France: International Agency for Research 
on Cancer. Cancer Today 2016 Available from: http://gco.iarc.
fr/today. Accessed January 22, 2018.
17. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, 
Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence 
and mortality worldwide: Sources, methods and major patterns 
in GLOBOCAN 2012. Int J Cancer 136: E359-E386, 2015.
18. Center MM, Jemal A, Lortet-Tieulent J, ward E, Ferlay J, 
Brawlt O and Bray F: International variation in prostate cancer 
incidence and mortality rates. Eur Urol 61: 1079-1092, 2012.
19. Nelson EC, Cambio AJ, Yang JC, Ok JH, Lara PN Jr and 
Evans CP: Clinical implications of neuroendocrine differentia-
tion in prostate cancer. Prostate Cancer Prostatic Dis 10: 6-14, 
2007.
20. Foster HA, Davies J, Pink RC, Turkcigdem S, Goumenou A, 
Carter DR, Saunders NJ, Thomas P and Karteris E: The human 
myometrium differentially expresses mTOR signalling compo-
nents before and during pregnancy: Evidence for regulation by 
progesterone. J Steroid Biochem Mol Biol 139: 166-172, 2014.
21. Johnson TR, Khandrika L, Kumar B, Venezia S, Koul S, 
Chandhoke R, Maroni P, Donohue R, Meacham RB and 
Koul HK: Focal adhesion kinase controls aggressive phenotype 
of androgen-independent prostate cancer. Mol Cancer Res 6: 
1639-1648, 2008.
22. Chen Y, Xin X, Li J, Xu J, Yu X, Li T, Mo Z and Hu Y: RTK/ERK 
pathway under natural selection associated with prostate cancer. 
PLoS One 8: e78254, 2013.
23. Li wH, Qiu Y, Zhang HQ, Tian XX and Fang wG: P2Y2 receptor 
and EGFR cooperate to promote prostate cancer cell invasion via 
ERK1/2 pathway. PLoS One 10: e0133165, 2015.
24. Ghosh PM, Malik SN, Bedolla RG, wang Y, Mikhailova M, 
Prihoda TJ, Troyer DA and Kreisberg JI: Signal transduction 
pathways in androgen-dependent and -independent prostate 
cancer cell proliferation. Endocr Relat Cancer 12: 119-134, 2005.
25. McCubrey JA, Steelman LS, Abrams SL, Bertrand FE, 
Ludwig DE, Bäsecke J, Libra M, Stivala F, Milella M, Tafuri A, 
et al: Targeting survival cascades induced by activation of 
Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT 
pathways for effective leukemia therapy. Leukemia 22: 708-722, 
2008.
26. Tibbles LA and woodgett JR: The stress-activated protein kinase 
pathways. Cell Mol Life Sci 55: 1230-1254, 1999.
27. Ricote M, García-Tuñón I, Fraile B, Fernández C, Aller P, 
Paniagua R and Royuela M: P38 MAPK protects against 
TNF-alpha-provoked apoptosis in LNCaP prostatic cancer cells. 
Apoptosis 11: 1969-1975, 2006.
28. Koul HK, Pal M and Koul S: Role of p38 MAP Kinase signal 
transduction in solid tumors. Genes Cancer 4: 342-359, 2013.
29. Lotan TL, Lyon M, Huo D, Taxy JB, Brendler C, Foster BA, 
Stadler w and Rinker-Schaeffer Cw: Up-regulation of MKK4, 
MKK6 and MKK7 during prostate cancer progression: An 
important role for SAPK signalling in prostatic neoplasia. 
J Pathol 212: 386-394, 2007.
30. Magi-Galluzzi C, Mishra R, Fiorentino M, Montironi R, Yao H, 
Capodieci P, wishnow K, Kaplan I, Stork PJ and Loda M: 
Mitogen-activated protein kinase phosphatase 1 is overexpressed 
in prostate cancers and is inversely related to apoptosis. Lab 
Invest 76: 37-51, 1997.
31. Boldt S, weidle UH and Kolch w: The role of MAPK pathways 
in the action of chemotherapeutic drugs. Carcinogenesis 23: 
1831-1838, 2002.
32. Xia Z, Dickens M, Raingeaud J, Davis RJ and Greenberg ME: 
Opposing effects of ERK and JNK-p38 MAP kinases on apop-
tosis. Science 270: 1326-1331, 1995.
33. Xu L, Chen S and Bergan RC: MAPKAPK2 and HSP27 are 
downstream effectors of p38 MAP kinase-mediated matrix 
metalloproteinase type 2 activation and cell invasion in human 
prostate cancer. Oncogene 25: 2987-2998, 2006.
34. Chen L, He HY, Li HM, Zheng J, Heng wJ, You JF and Fang wG: 
ERK1/2 and p38 pathways are required for P2Y receptor-medi-
ated prostate cancer invasion. Cancer Lett 215: 239-247, 2004.
35. Gururajan M, Chui R, Karuppannan AK, Ke J, Jennings CD 
and Bondada S: c-Jun N-terminal kinase (JNK) is required for 
survival and proliferation of B-lymphoma cells. Blood 106: 
1382-1391, 2005.
36. Shimada K, Nakamura M, Ishida E, Kishi M, Yonehara S and 
Konishi N: c-Jun NH2-terminal kinase-dependent Fas activa-
tion contributes to etoposide-induced apoptosis in p53-mutated 
prostate cancer cells. Prostate 55: 265-280, 2003.
37. Rodríguez-Berriguete G, Fraile B, Martínez-Onsurbe P, 
Olmedilla G, Paniagua R and Royuela M: MAP kinases and 
prostate cancer. J Signal Transduct 2012: 169170, 2012.
38. Davis RJ: Signal transduction by the JNK group of MAP kinases. 
Cell 103: 239-252, 2000.
39. Sui X, Kong N, Ye L, Han w, Zhou J, Zhang Q, He C and Pan H: 
p38 and JNK MAPK pathways control the balance of apoptosis 
and autophagy in response to chemotherapeutic agents. Cancer 
Lett 344: 174-179, 2014.
40. Guo J, Zhu T, Chen L, Nishioka T, Tsuji T, Xiao ZX and Chen CY: 
Differential sensitization of different prostate cancer cells to 
apoptosis. Genes Cancer 1: 836-846, 2010.
41. Shukla S, Maclennan GT, Hartman DJ, Fu P, Resnick MI and 
Gupta S: Activation of PI3K-Akt signaling pathway promotes 
prostate cancer cell invasion. Int J Cancer 121: 1424-1432, 2007.
42. Toren P and Zoubeidi A: Targeting the PI3K/Akt pathway in 
prostate cancer: Challenges and opportunities (Review). Int 
J Oncol 45: 1793-1801, 2014.
43. Gan Y, Shi C, Inge L, Hibner M, Balducci J and Huang Y: 
Differential roles of ERK and Akt pathways in regulation of 
EGFR-mediated signaling and motility in prostate cancer cells. 
Oncogene 29: 4947-4958, 2010.
44. Yao Huang and Yongchang Chang: Epidermal Growth Factor 
Receptor (EGFR) Phosphorylation, Signaling and Trafficking 
in Prostate Cancer. Prostate Cancer-From Bench to Bedside. 
Dr. Philippe E. Spiess (ed). InTech, doi: 10.5772/27021, 2011.
45. Ding G, Fang J, Tong S, Qu L, Jiang H, Ding Q and Liu J: 
Over-expression of lipocalin 2 promotes cell migration and 
invasion through activating ERK signalling to increase SLUG 
expression in prostate cancer. Prostate 75: 957-968, 2015.
46. Ljujic  M, Mijatovic S,  Bulatovic M Z, Mojic M, 
Maksimovic-Ivanic D, Radojkovic D and Topic A: Alpha-1- 
antitrypsin antagonizes cisplatin-induced cytotoxicity in prostate 
cancer (PC3) and melanoma cancer (A375) cell lines. Pathol 
Oncol Res 23: 335-343, 2017.
47. Rybak AP, Ingram AJ and Tang D: Propagation of human pros-
tate cancer stem-like cells occurs through EGFR-mediated ERK 
activation. PLoS One 8: e61716, 2013.
48. Xiao LJ, Lin P, Lin F, Liu X, Qin w, Zou HF, Guo L, Liu w, 
wang SJ and Yu XG: ADAM17 targets MMP-2 and MMP-9 via 
EGFR-MEK-ERK pathway activation to promote prostate cancer 
cell invasion. Int J Oncol 40: 1714-1724, 2012.
49. Moulik S, Pal S, Biswas J and Chatterjee A: Role of ERK in 
modulating MMP 2 and MMP 9 with respect to tumour inva-
siveness in human cancer cell line MCF-7 and MDA-MB-231. 
Journal of Tumor 2: 87-98, 2014.
50. Yang JL, Lin JH, weng Sw, Chen JC, Yang JS, Amagaya S, 
Funayana S, wood wG, Kuo CL and Chung JG: Crude extract 
of Euphorbia formosana inhibits the migration and invasion of 
DU145 human prostate cancer cells: The role of matrix metallo-
proteinase-2/9 inhibition via the MAPK signaling pathway. Mol 
Med Rep 7: 1403-1408, 2013.
51. Huang X, Chen S, Xu L, Liu Y, Deb DK, Platanias LC and 
Bergan RC: Genistein inhibits p38 map kinase activation, matrix 
metalloproteinase type 2, and cell invasion in human prostate epithe-
lial cells. Cancer Res 65: 3470-3478, 2005.
52. Oguic R, Mozetič V, Cini Tešar E, Fučkar Čupić D, Mustać E 
and Dorđević G: Matrix metalloproteinases 2 and 9 immunoex-
pression in prostate carcinoma at the positive margin of radical 
prostatectomy specimens. Patholog Res Int 2014: 262195, 2014.
53. Trudel D, Fradet Y, Meyer F, Harel F and Têtu B: Significance of 
MMP-2 expression in prostate cancer: An immunohistochemical 
study. Cancer Res 63: 8511-8515, 2003.
ONCOLOGY REPORTS  41:  1140-1150,  20191150
54. Kyrou I, Randeva HS and weickert MO: Clinical Problems 
Caused by Obesity. In: De Groot LJ, Chrousos G, Dungan K, 
Feingold KR, Grossman A, Hershman JM, Koch C, Korbonits M, 
McLachlan R, New M, Purnell J, Rebar R, Singer F, Vinik A, 
editors. South Dartmouth (MA): MDText.com, Inc. 2014. 
Available on Endotext [Internet].
55. Kyrou I, Mattu HS, Chatha K and Randeva HS: Chapter 7-Fat 
Hormones, Adipokines. In Schisler JC, Lang CH, willis MS 
(eds). Endocrinology of the Heart in Health and Disease. 
Academic Press 2017: 167-205, 2017.
56. Alshaker H, Sacco K, Alfraidi A, Muhammad A, winkler M 
and Pchejetski D: Leptin signalling, obesity and prostate 
cancer: Molecular and clinical perspective on the old dilemma. 
Oncotarget 6: 35556-35563, 2015.
57. Baillargeon J and Rose DP: Obesity, adipokines, and prostate 
cancer (Review). Int J Oncol 28: 737-745, 2006.
58. Szyszka M, Tyczewska M, Milecka P, Jopek K, Celichowski P, 
Malendowicz LK and Rucinski M: Effects of leptin on leptin 
receptor isoform expression and proliferative activity in human 
normal prostate and prostate cancer cell lines. Oncol Rep 39: 
182-192, 2018.
59. Hoda MR, Theil G, Mohammed N, Fischer K and Fornara P: 
The adipocyte-derived hormone leptin has proliferative actions 
on androgen-resistant prostate cancer cells linking obesity to 
advanced stages of prostate cancer. J Oncol 280386, 2012.
60. Onuma M, Bub JD, Rummel TL and Iwamoto Y: Prostate cancer 
cell-adipocyte interaction: Leptin mediates androgen-inde-
pendent prostate cancer cell proliferation through c-Jun 
NH2-terminal kinase. J Biol Chem 278: 42660-42667, 2003.
61. Miyazaki T, Bub JD and Iwamoto Y: c-Jun NH2-terminal kinase mediates leptin-stimulated androgen-independent prostate 
cancer cell proliferation via signal transducer and activator of 
transcription 3 and Akt. Biochim Biophys Acta 1782: 593-604, 
2008.
This work is licensed under a Creative Commons 
Attribution 4.0 International (CC BY 4.0) License.
